-+ 0.00%
-+ 0.00%
-+ 0.00%

NeoGenomics Launched RaDaR ST, Circulating Tumor DNA Assay For Detecting Molecular Residual Disease

Benzinga·02/25/2026 12:15:03
Listen to the news

The company estimates that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated